Obtaining approval to commence a First-In-Human Ph1 clinical study is a significant achievement and endorsement of the pre clinical toxicology and expected safety in humans of the product.
The program will be scrutinised by the scientific and ethics review committee, which typically will contain a toxicologist.
The probability of success in Ph1 is quite high.
The preclinical efficacy data is nothing but remarkable. A positive Ph1 safety outcome and we'll be easily north of $1. With results expected within 9 months.
Huge potential with this counter...
Obtaining approval to commence a First-In-Human Ph1 clinical...
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
